Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) yields positive results for cancer against the surrounding tissues. The combination of DWIBS and T2-weighted images (DWIBS/T2) in the diagnosis of gastrointestinal tract cancers was retrospectively analyzed in the present study. Patients were subjected to magnetic resonance imaging after cancer was diagnosed through specimens obtained via biopsy or endoscopic mucosal resection. Sixteen patients were assessed between July, 2012 and June, 2013 and the correlation between detection with DWIBS/T2 and T staging was analyzed. Regarding patients who underwent surgery, the correlation between detection with DWIBS/T2 and the diameter or depth of invasion was analyzed. All cancers that had advanced to >T2 stage were detectable by DWIBS/T2, whereas all cancers staged as
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906954 | PMC |
http://dx.doi.org/10.3892/mco.2016.897 | DOI Listing |
Introduction Tumor staging is essential for determining treatment strategies and predicting prognosis in cancer patients. Accurate imaging techniques are critical for staging, metastasis screening, treatment response assessment, and recurrence detection. Objective In this prospective study, we aimed to compare the sensitivity of whole-body diffusion-weighted imaging (WB-DWI) with positron emission tomography/computed tomography (PET/CT) in detecting metastases.
View Article and Find Full Text PDFMod Rheumatol Case Rep
December 2024
Department of Orthopaedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Patients with rheumatoid arthritis (RA) receiving immunosuppressive therapy including methotrexate (MTX), are at risk of developing lymphoproliferative disorder (LPD). Herein, we report the case of a 61-year-old man who has been treated with MTX and sulfasalazine for seropositive RA since the age of 52. He underwent diffusion-weighted whole-body imaging with background signal suppression (DWIBS), which revealed high-intensity lesions in the affected lymph nodes of the cervical, clavicular, and axillary regions.
View Article and Find Full Text PDFEur Radiol Exp
November 2024
Department of Radiology, Medical University Innsbruck, Innsbruck, Austria.
Background: To investigate the artifact sizes of four common breast clip-markers on a standard breast magnetic resonance imaging (MRI) protocol in an in vitro phantom model.
Methods: Using 1.5-T and 3-T whole-body scanners with an 18-channel breast coil, artifact dimensions of four breast biopsy markers in an agarose-gel phantom were measured by two readers on images obtained with the following sequences: T2-weighted fast spin-echo short inversion time fat-suppressed inversion-recovery with magnitude reconstruction (T2-TIRM); T1-weighted spoiled gradient-echo with fat suppression (T1_FL3D), routinely used for dynamic contrast-enhanced imaging; diffusion-weighted imaging (DWI), including a readout segmented echo-planar imaging (RESOLVE-DWI) and echo-planar imaging sequence (EPI-DWI).
EJNMMI Rep
November 2024
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
Background: To investigate the ability of artificial intelligence (AI)-based and semi-quantitative dynamic contrast enhanced (DCE) multiparametric MRI (mpMRI), performed within [F]-PSMA-1007 PET/MRI, in differentiating benign from malignant prostate tissues in patients with primary prostate cancer (PC).
Results: A total of seven patients underwent whole-body [F]-PSMA-1007 PET/MRI examinations including a pelvic mpMRI protocol with T2w, diffusion weighted imaging (DWI) and DCE image series. Conventional analysis included visual reading of PET/MRI images and Prostate Imaging Reporting & Data System (PI-RADS) scoring of the prostate.
Magn Reson Med
March 2025
Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, Cardiff, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!